Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $117,142.04 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 2,602 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $45.02, for a total value of $117,142.04. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at $564,820.92. The trade was a 17.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded down $1.44 during trading on Wednesday, hitting $43.52. 523,927 shares of the company were exchanged, compared to its average volume of 698,512. The firm has a market capitalization of $3.30 billion, a P/E ratio of 96.71 and a beta of 0.06. The firm’s fifty day moving average price is $41.78 and its 200 day moving average price is $38.06. Kiniksa Pharmaceuticals International, plc has a 1-year low of $18.12 and a 1-year high of $45.50.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm’s revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.18) EPS. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $20,349,000. Qube Research & Technologies Ltd increased its holdings in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Kiniksa Pharmaceuticals International by 288.6% in the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after acquiring an additional 402,078 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

KNSA has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.